157 related articles for article (PubMed ID: 32951115)
1. Uninterrupted use of direct oral anticoagulants versus vitamin K antagonists for catheter ablation of atrial fibrillation with PVAC gold: incidence of silent cerebral microembolic events.
Wieczorek M; Bogossian H; Bandorski D; Hoeltgen R
J Interv Card Electrophysiol; 2021 Oct; 62(1):39-47. PubMed ID: 32951115
[TBL] [Abstract][Full Text] [Related]
2. Cerebral thromboembolic risk in atrial fibrillation ablation: a direct comparison of vitamin K antagonists versus non-vitamin K-dependent oral anticoagulants.
Petzl A; Derndorfer M; Kollias G; Moroka K; Aichinger J; Pürerfellner H; Martinek M
J Interv Card Electrophysiol; 2021 Jan; 60(1):147-154. PubMed ID: 32144677
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with silent cerebral events during atrial fibrillation ablation in patients on uninterrupted oral anticoagulation.
Harada M; Motoike Y; Nomura Y; Nishimura A; Koshikawa M; Murayama K; Ohno Y; Watanabe E; Ozaki Y; Izawa H
J Cardiovasc Electrophysiol; 2020 Nov; 31(11):2889-2897. PubMed ID: 32786019
[TBL] [Abstract][Full Text] [Related]
4. Impact of periprocedural anticoagulation strategy on the incidence of new-onset silent cerebral events after radiofrequency catheter ablation of atrial fibrillation.
Müller P; Halbfass P; Szöllösi A; Dietrich JW; Fochler F; Nentwich K; Roos M; Krug J; Schmitt R; Mügge A; Deneke T
J Interv Card Electrophysiol; 2016 Sep; 46(3):203-11. PubMed ID: 27020439
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation.
Mao YJ; Wang H; Huang PF
J Interv Card Electrophysiol; 2021 Apr; 60(3):407-417. PubMed ID: 32361948
[TBL] [Abstract][Full Text] [Related]
6. Incidence and Clinical Significance of Cerebral Embolism During Atrial Fibrillation Ablation With Duty-Cycled Phased-Radiofrequency Versus Cooled-Radiofrequency: A Randomized Controlled Trial.
Keçe F; Bruggemans EF; de Riva M; Alizadeh Dehnavi R; Wijnmaalen AP; Meulman TJ; Brugman JA; Rooijmans AM; van Buchem MA; Middelkoop HA; Eikenboom J; Schalij MJ; Zeppenfeld K; Trines SA
JACC Clin Electrophysiol; 2019 Mar; 5(3):318-326. PubMed ID: 30898234
[TBL] [Abstract][Full Text] [Related]
7. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation.
Cardoso R; Knijnik L; Bhonsale A; Miller J; Nasi G; Rivera M; Blumer V; Calkins H
Heart Rhythm; 2018 Jan; 15(1):107-115. PubMed ID: 28917562
[TBL] [Abstract][Full Text] [Related]
8. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation.
De Heide J; Vroegh CJ; Bhagwandien RE; Wijchers SA; Szili-Torok T; Zijlstra F; Lenzen MJ; Yap SC
J Interv Card Electrophysiol; 2018 Dec; 53(3):341-346. PubMed ID: 30074120
[TBL] [Abstract][Full Text] [Related]
9. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G
Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498
[TBL] [Abstract][Full Text] [Related]
10. Low rate of asymptomatic cerebral embolism and improved procedural efficiency with the novel pulmonary vein ablation catheter GOLD: results of the PRECISION GOLD trial.
De Greef Y; Dekker L; Boersma L; Murray S; Wieczorek M; Spitzer SG; Davidson N; Furniss S; Hocini M; Geller JC; Csanádi Z;
Europace; 2016 May; 18(5):687-95. PubMed ID: 26826134
[TBL] [Abstract][Full Text] [Related]
11. Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis.
Nairooz R; Ayoub K; Sardar P; Payne J; Almomani A; Pothineni NV; Shailesh F; Aronow WS; Mukherjee D
Can J Cardiol; 2016 Jun; 32(6):814-23. PubMed ID: 26810476
[TBL] [Abstract][Full Text] [Related]
12. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
13. Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study.
Tang L; Liu H; Deng H; Zhan X; Fang X; Liao H; Liu Y; Fu L; Fu Z; Liu H; Wu S; Xue Y
Front Med (Lausanne); 2020; 7():197. PubMed ID: 32582721
[No Abstract] [Full Text] [Related]
14. Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial.
Hohnloser SH; Camm AJ; Cappato R; Diener HC; Heidbüchel H; Mont L; Morillo CA; Lanz HJ; Rauer H; Reimitz PE; Smolnik R; Kautzner J
Europace; 2021 Jan; 23(1):65-72. PubMed ID: 33249467
[TBL] [Abstract][Full Text] [Related]
15. Non-vitamin K oral anticoagulants in hypertrophic cardiomyopathy patients undergoing catheter ablation of atrial fibrillation.
Creta A; Hunter RJ; Earley MJ; Finlay M; Dhinoja M; Sporton S; Chow A; Mohiddin SA; Boveda S; Adragao P; Jebberi Z; Matos D; Schilling RJ; Lambiase PD; Providência R
J Cardiovasc Electrophysiol; 2020 Oct; 31(10):2626-2631. PubMed ID: 32639666
[TBL] [Abstract][Full Text] [Related]
16. Comparison of major bleeding events of uninterrupted non-vitamin K antagonist oral anticoagulants versus uninterrupted vitamin K antagonist during catheter ablation of atrial fibrillation: a meta-analysis of randomised controlled trials.
Yang Q; Chen X; Zhai J; Dang Y
Acta Cardiol; 2022 May; 77(3):257-263. PubMed ID: 33871328
[TBL] [Abstract][Full Text] [Related]
17. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
[TBL] [Abstract][Full Text] [Related]
18. Thromboembolism and bleeding risk in atrial fibrillation ablation with uninterrupted anticoagulation between new oral anticoagulants and vitamin K antagonists: insights from an updated meta-analysis.
Liu XH; Gao XF; Chen CF; Chen B; Xu YZ
J Thromb Thrombolysis; 2020 Jul; 50(1):201-210. PubMed ID: 31686297
[TBL] [Abstract][Full Text] [Related]
19. Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon.
Gaita F; Leclercq JF; Schumacher B; Scaglione M; Toso E; Halimi F; Schade A; Froehner S; Ziegler V; Sergi D; Cesarani F; Blandino A
J Cardiovasc Electrophysiol; 2011 Sep; 22(9):961-8. PubMed ID: 21453372
[TBL] [Abstract][Full Text] [Related]
20. [Oral anticoagulation in atrial fibrillation: differential therapy with non vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists (VKA)].
Sucker C; Litmathe J; Berthold HK
MMW Fortschr Med; 2019 Oct; 161(Suppl 6):15-23. PubMed ID: 31587168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
